Beam Therapeutics (BEAM) Retained Earnings (2019 - 2026)

Beam Therapeutics (BEAM) has reported Retained Earnings for 8 consecutive years, with -$1.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 1.44% year-over-year to -$1.7 billion; the TTM figure through Mar 2026 stood at -$1.7 billion (down 1.44% YoY), while the FY2025 annual figure was $1.1 million, down 99.95% from the prior year.
• Retained Earnings retreated to -$1.7 billion in Q1 2026 per BEAM's latest filing, from $1.1 million in the prior quarter.
• Across five years, Retained Earnings topped out at $2.9 billion in Q3 2025 and bottomed at -$1.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$67.5 million across 5 years, with a median of -$1.0 billion in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings slumped 2114624.0% — and 2023, when it jumped 325.36%.
• Beam Therapeutics' Retained Earnings stood at -$1.1 billion in 2022, then declined by 12.53% to -$1.2 billion in 2023, then soared by 293.18% to $2.3 billion in 2024, then plunged by 99.95% to $1.1 million in 2025, then slumped by 153115.3% to -$1.7 billion in 2026.
• Business Quant data shows BEAM's Retained Earnings at -$1.7 billion in Q1 2026, $1.1 million in Q4 2025, and $2.9 billion in Q3 2025.